{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T15:16:34Z","timestamp":1791299794492,"version":"4.1.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.dmd.2026.100381","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T06:40:11Z","timestamp":1785307211000},"page":"100381","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cyclosporine A, a macrocyclic peptide, is transported by organic anion transporting polypeptide 1B1\/1B3 at clinically relevant doses"],"prefix":"10.1016","volume":"54","author":[{"given":"Sumathy","family":"Mathialagan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8121-8746","authenticated-orcid":false,"given":"Sook Wah","family":"Yee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine C.","family":"Orozco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven Scott","family":"Gernhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5064-2006","authenticated-orcid":false,"given":"Emi","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3337-5488","authenticated-orcid":false,"given":"Mark A.","family":"West","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Sannino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy Brown","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1134-5711","authenticated-orcid":false,"given":"Ruth F.","family":"Sommese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5843-7959","authenticated-orcid":false,"given":"David A.","family":"Tess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9541-6329","authenticated-orcid":false,"given":"Manthena V.S.","family":"Varma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.dmd.2026.100381_bib1","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/0014-5793(94)01382-B","article-title":"Stimulation of transforming growth factor-beta 1 transcription by cyclosporine","volume":"358","author":"Prashar","year":"1995","journal-title":"FEBS Lett"},{"issue":"7","key":"10.1016\/j.dmd.2026.100381_bib2","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1016\/j.transproceed.2005.07.061","article-title":"The area under the concentration-time curve versus trough and peak blood level monitoring in renal transplant recipients on cyclosporine","volume":"37","author":"Halim","year":"2005","journal-title":"Transplant Proc"},{"key":"10.1016\/j.dmd.2026.100381_bib3","series-title":"StatPearls","article-title":"Cyclosporine","author":"Tapia","year":"2026"},{"issue":"3","key":"10.1016\/j.dmd.2026.100381_bib4","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/S0149-2918(02)85038-X","article-title":"Therapeutic drug monitoring of immunosuppressant drugs in clinical practice","volume":"24","author":"Kahan","year":"2002","journal-title":"Clin Ther"},{"issue":"4","key":"10.1016\/j.dmd.2026.100381_bib5","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1177\/039463201002300421","article-title":"Bioavailability of Sandimmun\u00ae versus Sandimmun Neoral\u00ae: a meta-analysis of published studies","volume":"23","author":"Colombo","year":"2010","journal-title":"Int J Immunopathol Pharmacol"},{"issue":"1-2","key":"10.1016\/j.dmd.2026.100381_bib6","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ijpharm.2013.05.033","article-title":"From gut to kidney: transporting and metabolizing calcineurin-inhibitors in solid organ transplantation","volume":"452","author":"Knops","year":"2013","journal-title":"Int J Pharm"},{"issue":"4","key":"10.1016\/j.dmd.2026.100381_bib7","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1208\/s12248-013-9500-8","article-title":"Population pharmacokinetics of cyclosporine in transplant recipients","volume":"15","author":"Han","year":"2013","journal-title":"AAPS J"},{"issue":"6","key":"10.1016\/j.dmd.2026.100381_bib8","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1007\/s00228-013-1471-2","article-title":"Effect of itraconazole on the concentrations of tacrolimus and cyclosporine in the blood of patients receiving allogeneic hematopoietic stem cell transplants","volume":"69","author":"Nara","year":"2013","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.dmd.2026.100381_bib9","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.healun.2010.09.001","article-title":"Pharmacokinetic drug\u2013drug interactions between calcineurin inhibitors and proliferation signal inhibitors with anti-microbial agents: implications for therapeutic drug monitoring","volume":"30","author":"Page","year":"2011","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.dmd.2026.100381_bib10","series-title":"Drug interaction studies M12","year":"2025"},{"issue":"5","key":"10.1016\/j.dmd.2026.100381_bib11","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1002\/cpt.3564","article-title":"Navigating the challenges of cyclosporine as an alternative to rifampicin as an OATP1B index inhibitor","volume":"117","author":"Varma","year":"2025","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.dmd.2026.100381_bib12","doi-asserted-by":"crossref","first-page":"26","DOI":"10.7812\/TPP\/06-018","article-title":"How can we manage hyperlipidemia and avoid rhabdomyolysis in transplant patients?","volume":"10","author":"Kahwaji","year":"2006","journal-title":"Perm J"},{"issue":"6","key":"10.1016\/j.dmd.2026.100381_bib13","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.trsl.2013.08.003","article-title":"Interaction of immunosuppressive drugs with human organic anion transporter (OAT) 1 and OAT3, and multidrug resistance-associated protein (MRP) 2 and MRP4","volume":"162","author":"El-Sheikh","year":"2013","journal-title":"Transl Res"},{"issue":"4","key":"10.1016\/j.dmd.2026.100381_bib14","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1124\/dmd.106.011866","article-title":"Interactions of cyclosporin A with breast cancer resistance protein","volume":"35","author":"Xia","year":"2007","journal-title":"Drug Metab Dispos"},{"issue":"9","key":"10.1016\/j.dmd.2026.100381_bib15","doi-asserted-by":"crossref","first-page":"6077","DOI":"10.1016\/S0021-9258(18)53221-X","article-title":"Human P-glycoprotein transports cyclosporin A and FK506","volume":"268","author":"Saeki","year":"1993","journal-title":"J Biol Chem"},{"issue":"5","key":"10.1016\/j.dmd.2026.100381_bib16","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1124\/dmd.121.000783","article-title":"Experimental and modeling evidence supporting the trans-inhibition mechanism for preincubation time-dependent, long-lasting inhibition of organic anion transporting polypeptide 1B1 by cyclosporine A","volume":"50","author":"Izumi","year":"2022","journal-title":"Drug Metab Dispos"},{"issue":"11","key":"10.1016\/j.dmd.2026.100381_bib17","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1002\/jcph.70076","article-title":"Development of a physiologically based pharmacokinetic model to evaluate dosing regimens of cyclosporine as a precipitant of organic anion transporting polypeptide 1B (OATP1B)- and CYP3A4-mediated drug\u2013drug interactions","volume":"65","author":"Hegde","year":"2025","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.dmd.2026.100381_bib18","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1124\/jpet.119.257600","article-title":"Quantitative contribution of six major transporters to the hepatic uptake of drugs: \"SLC-phenotyping\" using primary human hepatocytes","volume":"370","author":"Bi","year":"2019","journal-title":"J Pharmacol Exp Ther"},{"issue":"5","key":"10.1016\/j.dmd.2026.100381_bib19","doi-asserted-by":"crossref","DOI":"10.1124\/dmd.123.001630","article-title":"Low molecular weight acids and OATP1B mediated hepatic clearance: in vitro and in vivo evaluation using novel hypoxia-inducible factor prolyl hydroxylase inhibitors (dustats)","volume":"52","author":"Bi","year":"2024","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"10.1016\/j.dmd.2026.100381_bib20","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1208\/s12248-017-0051-2","article-title":"Reliable rate measurements for active and passive hepatic uptake using plated human hepatocytes","volume":"19","author":"Bi","year":"2017","journal-title":"AAPS J"},{"issue":"4","key":"10.1016\/j.dmd.2026.100381_bib21","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1124\/dmd.116.074294","article-title":"Quantitative prediction of human renal clearance and drug-drug interactions of organic anion transporter substrates using in vitro transport data: a relative activity factor approach","volume":"45","author":"Mathialagan","year":"2017","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"10.1016\/j.dmd.2026.100381_bib22","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1097\/TP.0b013e3182215ec3","article-title":"Rhabdomyolysis after kidney transplantation caused by elevated serum cyclosporine due to metabolic enzyme and transporters disorder","volume":"92","author":"Kato","year":"2011","journal-title":"Transplantation"},{"issue":"5","key":"10.1016\/j.dmd.2026.100381_bib23","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1097\/00007691-200410000-00010","article-title":"CYP3A5 polymorphism and the ethnic differences in cyclosporine pharmacokinetics in healthy subjects","volume":"26","author":"Min","year":"2004","journal-title":"Ther Drug Monit"},{"issue":"5","key":"10.1016\/j.dmd.2026.100381_bib24","doi-asserted-by":"crossref","first-page":"823","DOI":"10.3390\/jpm12050823","article-title":"Evaluation of pharmacogenetics of drug-metabolizing enzymes and drug efflux transporter in renal transplants receiving immunosuppressants","volume":"12","author":"Sridharan","year":"2022","journal-title":"J Pers Med"},{"key":"10.1016\/j.dmd.2026.100381_bib25","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.ejps.2015.05.011","article-title":"CYP3A4\u221718B and CYP3A5\u22173 polymorphisms contribute to pharmacokinetic variability of cyclosporine among healthy Chinese subjects","volume":"76","author":"Tao","year":"2015","journal-title":"Eur J Pharm Sci"},{"issue":"3","key":"10.1016\/j.dmd.2026.100381_bib26","doi-asserted-by":"crossref","first-page":"36","DOI":"10.12659\/AOT.883456","article-title":"Impact of CYP3A4\u22171B and CYP3A5\u22173 polymorphisms on the pharmacokinetics of cyclosporine and sirolimus in renal transplant recipients","volume":"17","author":"\u017bochowska","year":"2012","journal-title":"Ann Transplant"},{"issue":"2","key":"10.1016\/j.dmd.2026.100381_bib27","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/00007890-198702000-00020","article-title":"Exacerbation of cyclosporine toxicity by concomitant administration of erythromycin","volume":"43","author":"Jensen","year":"1987","journal-title":"Transplantation"},{"issue":"2","key":"10.1016\/j.dmd.2026.100381_bib28","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1046\/j.1365-2125.1997.54310.x","article-title":"The mechanism of cyclosporine toxicity induced by clarithromycin","volume":"43","author":"Spicer","year":"1997","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.dmd.2026.100381_bib29","doi-asserted-by":"crossref","first-page":"319","DOI":"10.2165\/00003088-199019040-00004","article-title":"Pharmacokinetic drug interactions with cyclosporin (part I)","volume":"19","author":"Yee","year":"1990","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"10.1016\/j.dmd.2026.100381_bib30","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1124\/dmd.114.059105","article-title":"Investigation of the impact of substrate selection on in vitro organic anion transporting polypeptide 1B1 inhibition profiles for the prediction of drug-drug interactions","volume":"43","author":"Izumi","year":"2015","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"10.1016\/j.dmd.2026.100381_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2025.108484","article-title":"Cyclosporine A sterically inhibits statin transport by solute carrier OATP1B1","volume":"301","author":"Sung","year":"2025","journal-title":"J Biol Chem"},{"issue":"12","key":"10.1016\/j.dmd.2026.100381_bib32","doi-asserted-by":"crossref","first-page":"3785","DOI":"10.1007\/s11095-015-1749-4","article-title":"Predicting clearance mechanism in drug discovery: extended clearance classification system (ECCS)","volume":"32","author":"Varma","year":"2015","journal-title":"Pharm Res"},{"issue":"1","key":"10.1016\/j.dmd.2026.100381_bib33","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1124\/jpet.120.000457","article-title":"Organic anion\u2013transporting polypeptide 1B1\/1B3\u2013mediated hepatic uptake determines the pharmacokinetics of large lipophilic acids: in vitro\u2013in vivo evaluation in cynomolgus monkey","volume":"377","author":"Eng","year":"2021","journal-title":"J Pharmacol Exp Ther"},{"issue":"12","key":"10.1016\/j.dmd.2026.100381_bib34","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1097\/FPC.0b013e3283402efb","article-title":"Maraviroc is a substrate for OATP1B1 in vitro and maraviroc plasma concentrations are influenced by SLCO1B1 521 T>C polymorphism","volume":"20","author":"Siccardi","year":"2010","journal-title":"Pharmacogenet Genomics"},{"issue":"5","key":"10.1016\/j.dmd.2026.100381_bib35","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1124\/dmd.118.085241","article-title":"Mechanistic evaluation of the complex drug-drug interactions of maraviroc: contribution of cytochrome P450 3A, P-glycoprotein and organic anion transporting polypeptide 1B1","volume":"47","author":"Kimoto","year":"2019","journal-title":"Drug Metab Dispos"},{"issue":"10","key":"10.1016\/j.dmd.2026.100381_bib36","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00955-20","article-title":"Rifampicin transport by OATP1B1 variants","volume":"64","author":"Litjens","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"10.1016\/j.dmd.2026.100381_bib37","doi-asserted-by":"crossref","DOI":"10.1111\/cts.70048","article-title":"Deconvoluting zavegepant drug-drug interactions: a phase I study to evaluate the effects of rifampin and itraconazole on zavegepant pharmacokinetics","volume":"17","author":"Bhardwaj","year":"2024","journal-title":"Clin Transl Sci"},{"issue":"3","key":"10.1016\/j.dmd.2026.100381_bib38","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.taap.2004.08.012","article-title":"Organic anion transporting polypeptides expressed in liver and brain mediate uptake of microcystin","volume":"203","author":"Fischer","year":"2005","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/j.dmd.2026.100381_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmpk.2025.101055","article-title":"Comprehensive in vitro evaluation of the inhibitory effects of relatively high molecular weight peptides on drug-drug interaction-associated four liver transporters and its association with physicochemical properties","volume":"61","author":"Ishikawa","year":"2025","journal-title":"Drug Metab Pharmacokinet"},{"issue":"6","key":"10.1016\/j.dmd.2026.100381_bib40","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.3390\/biom13061002","article-title":"Identification of the stapled \u03b1-helical peptide ATSP-7041 as a substrate and strong inhibitor of OATP1B1 in vitro","volume":"13","author":"Ishikawa","year":"2023","journal-title":"Biomolecules"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955626006501?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955626006501?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T10:16:34Z","timestamp":1790331394000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955626006501"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":40,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0090955626006501"],"URL":"https:\/\/doi.org\/10.1016\/j.dmd.2026.100381","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cyclosporine A, a macrocyclic peptide, is transported by organic anion transporting polypeptide 1B1\/1B3 at clinically relevant doses","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmd.2026.100381","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society for Pharmacology and Experimental Therapeutics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"100381"}}